文献速递胃肠动力与功能性疾病

静脉补充类型与容量与慢性肠衰竭患者1年结局及主要并发症相关

Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure.
PubMed 文献 · Gut · 2020-01-21

分析显示静脉补充类型和容量均与脱离家庭肠外营养的几率、患者死亡、肠衰竭相关肝病胆汁淤积/肝衰竭及导管相关血流感染独立相关。

要点

  • 静脉补充类型和容量可能作为慢性肠衰竭严重程度的分类指标。
  • 肠外营养<1 L/天者脱离家庭肠外营养的几率显著高于单纯液体电解质及所有肠外营养>1 L/天者。
  • 肠外营养2-3 L/天和>3 L/天者肠衰竭相关肝病胆汁淤积/肝衰竭及导管相关血流感染发生率显著更高。

核心结论

  • 慢性肠衰竭患者所需的静脉补充类型和容量可能是临床实践和研究方案中分类慢性肠衰竭严重程度的指标。

研究设计与样本

  • 基线记录人口学数据、体重指数、慢性肠衰竭机制、基础疾病、家庭肠外营养时长及静脉补充类别。
  • 静脉补充类型分为单纯液体电解质或肠外营养混合液,平均每日静脉补充容量按周计算分为<1、1-2、2-3和>3 L/天。
  • 慢性肠衰竭严重程度由患者结局(仍在家庭肠外营养、脱离家庭肠外营养、死亡)及主要家庭肠外营养/慢性肠衰竭相关并发症确定。

主要发现

  • 静脉补充类型和容量均与脱离家庭肠外营养的几率独立相关,肠外营养<1 L/天者显著高于单纯液体电解质和所有肠外营养>1 L/天者。
  • 静脉补充类型和容量均与患者死亡独立相关,单纯液体电解质者死亡较低(p=0.079)。
  • 静脉补充类型和容量均与肠衰竭相关肝病胆汁淤积/肝衰竭及导管相关血流感染发生独立相关,肠外营养2-3 L/天和>3 L/天者显著更高。

关键数值与推荐

  • 静脉补充类型分类为单纯液体电解质或肠外营养混合液。
  • 平均每日静脉补充容量按周计算分为<1、1-2、2-3和>3 L/天。
  • 主要家庭肠外营养/慢性肠衰竭相关并发症包括肠衰竭相关肝病、导管相关静脉血栓和导管相关血流感染。

临床怎么用

  • 临床可依据慢性肠衰竭患者所需静脉补充的类型和容量评估疾病严重程度。
  • 对接受肠外营养2-3 L/天和>3 L/天者应警惕肠衰竭相关肝病胆汁淤积/肝衰竭及导管相关血流感染风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIM: No marker to categorise the severity of chronic intestinal failure (CIF) has been developed. A 1-year international survey was carried out to investigate whether the European Society for Clinical Nutrition and Metabolism clinical classification of CIF, based on the type and volume of the intravenous supplementation (IVS), could be an indicator of CIF severity. METHODS: At baseline, participating home parenteral nutrition (HPN) centres enrolled all adults with ongoing CIF due to non-malignant disease; demographic data, body mass index, CIF mechanism, underlying disease, HPN duration and IVS category were recorded for each patient. The type of IVS was classified as fluid and electrolyte alone (FE) or parenteral nutrition admixture (PN). The mean daily IVS volume, calculated on a weekly basis, was categorised as <1, 1-2, 2-3 and >3 L/day. The severity of CIF was determined by patient outcome (still on HPN, weaned from HPN, deceased) and the occurrence of major HPN/CIF-related complications: intestinal failure-associated liver disease (IFALD), catheter-related venous thrombosis and catheter-related bloodstream infection (CRBSI). RESULTS: Fifty-one HPN centres included 2194 patients. The analysis showed that both IVS type and volume were independently associated with the odds of weaning from HPN (significantly higher for PN <1 L/day than for FE and all PN >1 L/day), patients' death (lower for FE, p=0.079), presence of IFALD cholestasis/liver failure and occurrence of CRBSI (significantly higher for PN 2-3 and PN >3 L/day). CONCLUSIONS: The type and volume of IVS required by patients with CIF could be indicators to categorise the severity of CIF in both clinical practice and research protocols.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Pironi L, Steiger E, Joly F, et al. Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure. Gut. 2020. PMID: 31964752. doi:10.1136/gutjnl-2018-318172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。